ADAP vs. TNXP, ALLO, INZY, ALDX, CADL, ACB, SGMT, IMMP, CRDF, and FENC
Should you be buying Adaptimmune Therapeutics stock or one of its competitors? The main competitors of Adaptimmune Therapeutics include Tonix Pharmaceuticals (TNXP), Allogene Therapeutics (ALLO), Inozyme Pharma (INZY), Aldeyra Therapeutics (ALDX), Candel Therapeutics (CADL), Aurora Cannabis (ACB), Sagimet Biosciences (SGMT), Prima BioMed (IMMP), Cardiff Oncology (CRDF), and Adherex Technologies (FENC). These companies are all part of the "pharmaceutical products" industry.
Adaptimmune Therapeutics vs. Its Competitors
Tonix Pharmaceuticals (NASDAQ:TNXP) and Adaptimmune Therapeutics (NASDAQ:ADAP) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, dividends, earnings, media sentiment, valuation, risk, analyst recommendations and institutional ownership.
In the previous week, Tonix Pharmaceuticals had 15 more articles in the media than Adaptimmune Therapeutics. MarketBeat recorded 17 mentions for Tonix Pharmaceuticals and 2 mentions for Adaptimmune Therapeutics. Adaptimmune Therapeutics' average media sentiment score of 0.75 beat Tonix Pharmaceuticals' score of -0.12 indicating that Adaptimmune Therapeutics is being referred to more favorably in the news media.
Tonix Pharmaceuticals currently has a consensus price target of $585.00, indicating a potential upside of 1,281.02%. Adaptimmune Therapeutics has a consensus price target of $1.35, indicating a potential upside of 392.77%. Given Tonix Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts plainly believe Tonix Pharmaceuticals is more favorable than Adaptimmune Therapeutics.
Adaptimmune Therapeutics has a net margin of -38.91% compared to Tonix Pharmaceuticals' net margin of -1,313.87%. Tonix Pharmaceuticals' return on equity of -120.96% beat Adaptimmune Therapeutics' return on equity.
82.3% of Tonix Pharmaceuticals shares are held by institutional investors. Comparatively, 31.4% of Adaptimmune Therapeutics shares are held by institutional investors. 0.0% of Tonix Pharmaceuticals shares are held by company insiders. Comparatively, 12.7% of Adaptimmune Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Tonix Pharmaceuticals has a beta of 2.05, suggesting that its stock price is 105% more volatile than the S&P 500. Comparatively, Adaptimmune Therapeutics has a beta of 2.18, suggesting that its stock price is 118% more volatile than the S&P 500.
Adaptimmune Therapeutics has higher revenue and earnings than Tonix Pharmaceuticals. Adaptimmune Therapeutics is trading at a lower price-to-earnings ratio than Tonix Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Summary
Adaptimmune Therapeutics beats Tonix Pharmaceuticals on 9 of the 16 factors compared between the two stocks.
Get Adaptimmune Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ADAP and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding ADAP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartMedia Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Adaptimmune Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:ADAP) was last updated on 7/11/2025 by MarketBeat.com Staff